Alexandra Balcom
Net worth: 9 M $ as of 30/05/2026
Net worth: 9 M $ as of 30/05/2026
Ms. Alexandra Balcom is an Independent Director at Crescent Biopharma, Inc. and a Chief Financial Officer & Treasurer at Nuvalent, Inc. She is on the Board of Directors at Crescent Biopharma, Inc. Ms. Balcom was previously employed as a Vice President-Finance by SQZ Biotechnologies Co. and a Controller by Agios Pharmaceuticals, Inc. She also served on the board at Crescent Biopharma, Inc. (Old).
She received her undergraduate degree from the University of Massachusetts and an MBA from Boston College.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 30/06/2026 | 85,533 ( 0.12% ) | 9 M $ | 30/05/2026 | |
-.--% | 01/06/2026 | 0 ( -.--% ) | - $ | 30/05/2026 |
| Companies | Position | Start |
|---|---|---|
| NUVALENT, INC. | Director of Finance/CFO | 31/12/2020 |
| Companies | Position | End |
|---|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Corporate Officer/Principal | 28/02/2021 |
| AGIOS PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
SQZ Biotechnologies Co.
SQZ Biotechnologies Co. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops cell therapies for patients with cancer, infectious diseases and serious conditions | Health Technology |
Boston College
Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Massachusetts
University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nuvalent, Inc.
Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Select your edition
All financial news and data tailored to specific country editions